$FEMY

Lee-Sepsick Kathy purchased $50K of FEMY

Lee-Sepsick Kathy (Chief Executive Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Lee-Sepsick Kathy
Published Aug 12, 2026, 12:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FEMY
Neutral
low confidence
Mentioned
$FEMY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the disclosure alone does not provide new operational or financial information.

02

Market read

A small insider open-market buy is disclosed, which may marginally influence sentiment but is unlikely to drive a major repricing without additional fundamentals.

03

What to watch

The article does not state whether the purchase was part of any broader compensation or liquidity need, and it provides no follow-on guidance or operational catalyst.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-11 for a 2026-08-07 purchase

Background

The article is a SEC Form 4 insider transaction disclosure for FEMASYS Inc, reported via SEC EDGAR.

Company-level read

Ticker impact

$FEMYNeutralLow confidence
Context

CEO Kathy Lee-Sepsick filed a Form 4 open-market purchase of 15,625 shares at $3.20 on 2026-08-07, totaling $50,000.

Expected impact

Low likelihood of a sustained price move; any reaction is likely small and short-lived.

Evidence & confidence

This is a routine Form 4 insider transaction without a 10b5-1 plan and with relatively small dollar value, so it is unlikely to change fundamentals or guidance.

Market effects

No sector-level implications disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary or tax/portfolio-driven and may not reflect a change in business outlook, especially at small sizes.

Key entities

  • FEMASYS Inc

    Company whose CEO filed an insider open-market purchase on Form 4.

  • Lee-Sepsick Kathy

    CEO and director who purchased 15,625 shares at $3.20 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$FEMYMed

FEMASYS INC (FEMY): Results of Operations and Financial Condition

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

$FEMYMedAI 8/10

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.

$FEMYMedAI 8/10

Femasys Inc.: Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.